603392 万泰生物
2024/03 - 三个月
人民幣(K¥)
与去年同期
比较
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
2021/12
人民幣(K¥)
2020/12
人民幣(K¥)
营业总收入752,513-73.93%5,510,78311,185,1895,750,3292,354,257
减:营业总成本672,196-52.76%3,878,7175,747,9093,404,1151,587,661
    其中:营业成本202,777-16.30%792,1251,170,412817,711442,142
               财务费用(18,781)21.72%(92,977)(61,612)5,19511,367
               资产减值损失(9,156)-23.57%(459,733)(20,503)(29,841)(29,155)
公允价值变动收益3,983-27.68%24,6579,97728349
投资收益41,534242.27%98,89836,11311,22513,606
    其中:对联营企业和合营企业的投资收益----------2,247
营业利润127,921-91.08%1,401,4515,596,0382,328,456775,203
利润总额125,640-91.24%1,393,3925,582,6912,324,145764,452
减:所得税费用(4,144)-102.29%146,887719,390244,93182,636
净利润129,784-89.64%1,246,5044,863,3012,079,214681,815
减:非控股权益4,076-47.91%(1,175)127,50657,7474,818
股东净利润125,708-89.90%1,247,6804,735,7952,021,468676,997

市场价值指针
每股收益 (元) *0.100-89.90%0.9903.7902.3001.150
每股派息 (元) *----0.3201.0000.2000.250
每股净资产 (元) *10.106-32.60%10.01513.6217.3575.889
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容